Tuesday, September 29, 2015

#Micro Labs launches Caripill (priced at Rs 375/-) for treatment of #Dengue

Bangalore based Micro Labs has recently launched Caripill, which helps to increase the platelet count in patients suffering from Dengue.  Approved by the scientific and regulatory authority, the pill is made from Carica Papaya leaf extract and does not have any side-effects.  Being a product of extensive R & D and clinical trials conducted by Micro Labs,the pill has proved its safety and efficacy in about 1 lakh patients across India.
Priced at Rs 375 for a five-day course of 15 tablets (a unit), Caripill is primarily being marketed in the Delhi National Capital Region, Maharashtra and south Indian states, where many cases of dengue have been reported.
Dengue is emerging as a serious public health problem globally, with 2.5 billion people at risk and 50 million dengue infections occurring annually, according to a report from the World Health Organisation.Between January and June this year, five to six cases of dengue were reported in Hyderabad. However, the number now has touched 80 dengue cases between June and August.

Speaking about Caripill, Dr. A.C. Gowda Fortis Hospital, Bangalore and Principal Investigator, Clinical Trial for Caripill said, “The encouraging results on the dengue patients has shown the immense potential of what Caripill is capable of, after an extensive research and clinical trials on 250 patients, we have seen positive results with a dramatic decrease in the haemorrhage condition, besides, none of the patients who are administered the drug have had to undergo blood transfusion so far.”

Dilip Surana, Managing Director, Micro Labs Ltd.,stated that “Over 4 decades, we have been successful in manufacturing oral solids, liquids, topical and injectable medication for patients across verticals – diabetology, cardiology, ophthalmology, dermatology, pain/analgesics, etc."